Free CME from PeerView
Continuing Nursing Education (CNE) Activities
A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations
StartThis activity expired on March 12, 2025; credit is no longer available.
A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations
Media: Enduring Material
Activity Release Date: March 13, 2024
Activity Expiration Date: March 12, 2025
Time to Complete Activity: 60 minutes
Activity Description
While significant progress has been made in the management of severe
hemophilia A (HA), the needs of those with mild and moderate HA, including
females, have long been sidelined. Until now. Join two experts as they
explore the latest evidence with available pharmacologic treatment options,
including FVIII mimetics, that are paving the way for equitable HA care.
Through interactive case discussions, the experts will provide collaborative
solutions for overcoming challenges related to identifying, engaging, and
managing individuals with severe and non-severe HA to ensure no one is left
behind in the pursuit of equitable care.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, fellows, residents, and other healthcare professionals involved in the care of patients with hemophilia A.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize unmet needs and barriers to equitable HA care, including among severe, nonsevere, and female HA populations
- Summarize the evidence supporting established treatment options, including FVIII mimetic agents, with applications in diverse HA settings, including severe, nonsevere, and female HA populations
- Develop individualized HA treatment plans with established therapeutics based on disease severity, inhibitor status, gender, and age, among other considerations
- Employ principles of equitable, team-based, and participatory care when managing persons with HA, to ensure appropriate patient education, adherence counseling, and prompt management of disease- or treatment-related events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Amy Shapiro, MD
Medical Director and CEO
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana
Amy Shapiro, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech,
Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.;
Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin;
Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo
Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme;
Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La
Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of
the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the
National Hemophilia Program and Coordinating Center of the American
Thrombosis Hemostatis Network.
Faculty/Planner
Maissaa Janbain, MD, MSCR
Associate Professor of Clinical Medicine
Director
Tulane University
Deming Department of Medicine
Section of Hematology & Medical Oncology - Louisiana Center for Bleeding &
Clotting Disorders
New Orleans, Louisiana
Maissaa Janbain, MD, MSCR, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.;
Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation;
Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/12/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 12, 2025; credit is no longer available.
A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations
Media: Enduring Material
Activity Release Date: March 13, 2024
Activity Expiration Date: March 12, 2025
Time to Complete Activity: 60 minutes
Activity Description
While significant progress has been made in the management of severe
hemophilia A (HA), the needs of those with mild and moderate HA, including
females, have long been sidelined. Until now. Join two experts as they
explore the latest evidence with available pharmacologic treatment options,
including FVIII mimetics, that are paving the way for equitable HA care.
Through interactive case discussions, the experts will provide collaborative
solutions for overcoming challenges related to identifying, engaging, and
managing individuals with severe and non-severe HA to ensure no one is left
behind in the pursuit of equitable care.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, fellows, residents, and other healthcare professionals involved in the care of patients with hemophilia A.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize unmet needs and barriers to equitable HA care, including among severe, nonsevere, and female HA populations
- Summarize the evidence supporting established treatment options, including FVIII mimetic agents, with applications in diverse HA settings, including severe, nonsevere, and female HA populations
- Develop individualized HA treatment plans with established therapeutics based on disease severity, inhibitor status, gender, and age, among other considerations
- Employ principles of equitable, team-based, and participatory care when managing persons with HA, to ensure appropriate patient education, adherence counseling, and prompt management of disease- or treatment-related events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Amy Shapiro, MD
Medical Director and CEO
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana
Amy Shapiro, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech,
Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.;
Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin;
Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo
Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme;
Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La
Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of
the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the
National Hemophilia Program and Coordinating Center of the American
Thrombosis Hemostatis Network.
Faculty/Planner
Maissaa Janbain, MD, MSCR
Associate Professor of Clinical Medicine
Director
Tulane University
Deming Department of Medicine
Section of Hematology & Medical Oncology - Louisiana Center for Bleeding &
Clotting Disorders
New Orleans, Louisiana
Maissaa Janbain, MD, MSCR, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.;
Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation;
Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/12/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options
StartThis activity expired on March 10, 2025; credit is no longer available.
Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options
Media: Enduring Material
Activity Release Date: March 11, 2024
Activity Expiration Date: March 10, 2025
Time to Complete Activity: 30 minutes
Activity Description
Immunotherapy is now the centerpiece of modern, highly effective care for
malignant melanoma. The most recent development in the immunotherapy
revolution has centered on the validation of fixed-dose PD-1 and LAG-3
inhibitor combinations as an effective and safe frontline option for patients
requiring treatment for advanced disease. This has raised a number of
clinical questions related to the integration of PD-1/LAG-3 platforms into
treatment plans (alongside other immune combinations) and the role of
single-agent therapy.
This expert-led activity utilizes case-based teaching and short lectures to address these questions and provide guidance on incorporating the latest evidence on PD-1/LAG-3 therapy into practice, with the goal of illustrating the modern role of immune combinations in the frontline management of metastatic melanoma. The experts discuss how different baseline factors can inform treatment decisions made by the healthcare team, review the role of immunotherapy combinations in BRAF-mutant disease, and address practical aspects associated with the safe and effective delivery of dual checkpoint blockade with PD-1/LAG-3 platforms.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite updated guidelines and efficacy/safety evidence surrounding the use of newer immune-based approaches with PD-1/LAG-3 agents for unresectable and metastatic melanoma
- Implement personalized treatment plans that include PD-1/LAG-3 combination therapies for unresectable and metastatic melanoma, including in BRAF-mutant or BRAF wild-type disease
- Address practical aspects associated with newer dual checkpoint inhibition combinations, including irAE management and dosing, by working effectively in team-based care models
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Hussein Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
Co-Director, Andrew M. McDougall Brain Metastasis Clinic &
Program
Melanoma Medical Oncology | Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hussein Tawbi, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers
Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance
Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Dragonfly
Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline;
Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT
Therapeutics. Research Support to Institution.
Faculty/Planner
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS
Australian of the Year 2024
Co-Medical Director Melanoma Institute Australia
Professor of Melanoma Medical Oncology and Translational
Research
Melanoma Institute Australia, The University of Sydney, and Royal North
Shore & Mater Hospitals
Sydney, Australia
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a
financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array
Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG
(Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore;
Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre
Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX
B.V.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-035-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/10/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their
entirety and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 10, 2025; credit is no longer available.
Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options
Media: Enduring Material
Activity Release Date: March 11, 2024
Activity Expiration Date: March 10, 2025
Time to Complete Activity: 30 minutes
Activity Description
Immunotherapy is now the centerpiece of modern, highly effective care for
malignant melanoma. The most recent development in the immunotherapy
revolution has centered on the validation of fixed-dose PD-1 and LAG-3
inhibitor combinations as an effective and safe frontline option for patients
requiring treatment for advanced disease. This has raised a number of
clinical questions related to the integration of PD-1/LAG-3 platforms into
treatment plans (alongside other immune combinations) and the role of
single-agent therapy.
This expert-led activity utilizes case-based teaching and short lectures to address these questions and provide guidance on incorporating the latest evidence on PD-1/LAG-3 therapy into practice, with the goal of illustrating the modern role of immune combinations in the frontline management of metastatic melanoma. The experts discuss how different baseline factors can inform treatment decisions made by the healthcare team, review the role of immunotherapy combinations in BRAF-mutant disease, and address practical aspects associated with the safe and effective delivery of dual checkpoint blockade with PD-1/LAG-3 platforms.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite updated guidelines and efficacy/safety evidence surrounding the use of newer immune-based approaches with PD-1/LAG-3 agents for unresectable and metastatic melanoma
- Implement personalized treatment plans that include PD-1/LAG-3 combination therapies for unresectable and metastatic melanoma, including in BRAF-mutant or BRAF wild-type disease
- Address practical aspects associated with newer dual checkpoint inhibition combinations, including irAE management and dosing, by working effectively in team-based care models
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Hussein Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
Co-Director, Andrew M. McDougall Brain Metastasis Clinic &
Program
Melanoma Medical Oncology | Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hussein Tawbi, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers
Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance
Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Dragonfly
Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline;
Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT
Therapeutics. Research Support to Institution.
Faculty/Planner
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS
Australian of the Year 2024
Co-Medical Director Melanoma Institute Australia
Professor of Melanoma Medical Oncology and Translational
Research
Melanoma Institute Australia, The University of Sydney, and Royal North
Shore & Mater Hospitals
Sydney, Australia
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a
financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array
Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG
(Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore;
Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre
Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX
B.V.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-035-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/10/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their
entirety and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic
StartThis activity expired on March 7, 2025; credit is no longer available.
Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic
Media: Enduring Material
Activity Release Date: March 8, 2024
Activity Expiration Date: March 7, 2025
Time to Complete Activity: 30 minutes
Activity Description
In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
- Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
- Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Prof. Laurence Albiges, MD, PhD
Full Professor of Medical Oncology
Chair of Medical Oncology Department
Gustave Roussy Institute
Villejuif, France
Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US,
Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen
Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.;
Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-038-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their
entirety and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 7, 2025; credit is no longer available.
Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic
Media: Enduring Material
Activity Release Date: March 8, 2024
Activity Expiration Date: March 7, 2025
Time to Complete Activity: 30 minutes
Activity Description
In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
- Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
- Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Prof. Laurence Albiges, MD, PhD
Full Professor of Medical Oncology
Chair of Medical Oncology Department
Gustave Roussy Institute
Villejuif, France
Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US,
Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen
Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.;
Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-038-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their
entirety and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights
StartThis activity expired on March 4, 2025; credit is no longer available.
A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights
Media: Enduring Material
Activity Release Date: March 5, 2024
Activity Expiration Date: March 4, 2025
Time to Complete Activity: 60 minutes
Activity Description
HER2-targeting therapies are key components in the treatment of HER2-positive breast cancer. In this activity, a leading medical oncologist provides essential updates on the latest evidence and guideline recommendations for selecting and sequencing HER2-targeting therapies for HER2-positive metastatic breast cancer. In addition, real patient cases provide practical guidance for coordinating optimal breast cancer care across disciplines.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, advanced practice providers, nurses, and other healthcare professionals involved in the care of patients with breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the characteristics, mechanisms of action, and latest safety and efficacy findings supporting the use of approved and emerging HER2-targeted therapies for HER2-positive MBC
- Apply the latest evidence and guideline recommendations to optimally select and sequence HER2-targeting therapies for patients with HER2+ MBC, taking into account relevant treatment-, disease-, and patient-related factors
- Collaborate with the members of the multidisciplinary and interprofessional team to develop individualized treatment plans for patients with HER2+ MBC, monitor and manage TRAEs, and engage patients as informed participants in their care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Reshma L. Mahtani, DO
Chief of Breast Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance
Miami, Florida
Reshma L. Mahtani, DO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Agendia; Amgen Inc.;
AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; Hologic, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen
Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.
Grant/Research Support from AstraZeneca and Gilead
Sciences, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 4, 2025; credit is no longer available.
A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights
Media: Enduring Material
Activity Release Date: March 5, 2024
Activity Expiration Date: March 4, 2025
Time to Complete Activity: 60 minutes
Activity Description
HER2-targeting therapies are key components in the treatment of HER2-positive breast cancer. In this activity, a leading medical oncologist provides essential updates on the latest evidence and guideline recommendations for selecting and sequencing HER2-targeting therapies for HER2-positive metastatic breast cancer. In addition, real patient cases provide practical guidance for coordinating optimal breast cancer care across disciplines.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, advanced practice providers, nurses, and other healthcare professionals involved in the care of patients with breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the characteristics, mechanisms of action, and latest safety and efficacy findings supporting the use of approved and emerging HER2-targeted therapies for HER2-positive MBC
- Apply the latest evidence and guideline recommendations to optimally select and sequence HER2-targeting therapies for patients with HER2+ MBC, taking into account relevant treatment-, disease-, and patient-related factors
- Collaborate with the members of the multidisciplinary and interprofessional team to develop individualized treatment plans for patients with HER2+ MBC, monitor and manage TRAEs, and engage patients as informed participants in their care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Reshma L. Mahtani, DO
Chief of Breast Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance
Miami, Florida
Reshma L. Mahtani, DO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Agendia; Amgen Inc.;
AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; Hologic, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen
Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.
Grant/Research Support from AstraZeneca and Gilead
Sciences, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism
StartThis activity expired on February 28, 2025; credit is no longer available.
REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism
Media: Enduring Material
Activity Release Date: March 1, 2024
Activity Expiration Date: February 28, 2025
Time to Complete Activity: 45 minutes
Activity Description
Venous thromboembolism (VTE), is a significant complication in cancer
patients and a leading cause of mortality in this setting. Despite the
availability of numerous guidelines and resources for cancer-associated VTE
prevention and treatment, the uneven implementation of effective
anticoagulation remains a barrier to highly effective management.
In this PeerView virtual activity, a leading expert on cancer-associated VTE will provide clinical insights and case-based guidance on current prevention and treatment strategies for cancer-associated VTE. Throughout, the faculty will address modern prophylactic and therapeutic anticoagulation options, underscore the importance of risk assessment and timely management, and offer insights into the selection of anticoagulants. Additionally, the expert will highlight the importance of an interprofessional team-based approach, aligned with shared decision-making, when caring for patients at risk of cancer-associated VTE.
Target Audience
This activity has been designed to meet the educational needs of oncologists, NPs, PAs, and other care team clinicians involved in the prevention and management of cancer-associated VTE.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite recognized thromboembolic risk factors, guideline recommendations for modern risk assessment, and current evidence supporting modern anticoagulation strategies for cancer-associated VTE
- Implement risk-adapted prophylaxis and treatment strategies for cancer-associated VTE while employing the principles of equitable, team-based, and participatory care
- Manage practical aspects of VTE management in the cancer setting, including safe dosing and delivery of therapy, and provision of patient counseling on elevated VTE risks, adherence to treatment plans, and the risks/benefits of anticoagulation
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Alok A. Khorana, MD, FACP, FASCO
Sondra and Stephen Hardis Endowed Chair in Oncology Research
Vice-Chair, Taussig Cancer Center
Director, GI Malignancies Program
Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case
Western Reserve University
Cleveland, Ohio
Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Anthos Therapeutics; Bayer
Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/28/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 28, 2025; credit is no longer available.
REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism
Media: Enduring Material
Activity Release Date: March 1, 2024
Activity Expiration Date: February 28, 2025
Time to Complete Activity: 45 minutes
Activity Description
Venous thromboembolism (VTE), is a significant complication in cancer
patients and a leading cause of mortality in this setting. Despite the
availability of numerous guidelines and resources for cancer-associated VTE
prevention and treatment, the uneven implementation of effective
anticoagulation remains a barrier to highly effective management.
In this PeerView virtual activity, a leading expert on cancer-associated VTE will provide clinical insights and case-based guidance on current prevention and treatment strategies for cancer-associated VTE. Throughout, the faculty will address modern prophylactic and therapeutic anticoagulation options, underscore the importance of risk assessment and timely management, and offer insights into the selection of anticoagulants. Additionally, the expert will highlight the importance of an interprofessional team-based approach, aligned with shared decision-making, when caring for patients at risk of cancer-associated VTE.
Target Audience
This activity has been designed to meet the educational needs of oncologists, NPs, PAs, and other care team clinicians involved in the prevention and management of cancer-associated VTE.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite recognized thromboembolic risk factors, guideline recommendations for modern risk assessment, and current evidence supporting modern anticoagulation strategies for cancer-associated VTE
- Implement risk-adapted prophylaxis and treatment strategies for cancer-associated VTE while employing the principles of equitable, team-based, and participatory care
- Manage practical aspects of VTE management in the cancer setting, including safe dosing and delivery of therapy, and provision of patient counseling on elevated VTE risks, adherence to treatment plans, and the risks/benefits of anticoagulation
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Alok A. Khorana, MD, FACP, FASCO
Sondra and Stephen Hardis Endowed Chair in Oncology Research
Vice-Chair, Taussig Cancer Center
Director, GI Malignancies Program
Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case
Western Reserve University
Cleveland, Ohio
Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Anthos Therapeutics; Bayer
Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/28/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer
StartThis activity expired on March 23, 2025; credit is no longer available.
Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer
Media: Enduring Material
Activity Release Date: February 24, 2024
Activity Expiration Date: March 23, 2025
Time to Complete Activity: 60 minutes
Activity Description
Antibody-drug conjugates (ADCs) represent an exciting frontier in the
realm of precision lung cancer care, bringing hope to patients with limited
treatment options. The promise of these agents is now transitioning from
research settings to real-world practice, but many questions remain to be
answered by ongoing studies. In addition to the first HER2-targeting ADC
approved for HER2-mutated NSCLC, various other potent ADCs, such as those
targeting HER3, TROP2, B7-H3, among many others, are showing promising
activity in clinical trials, either as monotherapies or as integral parts of
combinations, spanning different settings and patient populations.
This unique educational activity, based on a recent live symposium, features
entertaining quiz-based Peer Pressure Challenges during which top experts are
put on the spot to compete against each other and test their knowledge about
ADCs. These game show segments are combined with related mini-lectures and
open discussion forums to review key concepts related to the ADCs, analyze
the latest evidence, examine unique nuances of using these therapies in
real-world practice, and explore the challenging issues and burning questions
about how to maximize the potential of ADCs in lung cancer.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other multidisciplinary and interprofessional healthcare providers involved in the care of patients with lung cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the clinical importance and biologic rationale for the use of different ADC-based approaches in lung cancer.
- Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of various ADCs in lung cancer.
- Integrate ADCs into treatment plans of carefully selected patients with lung cancer.
- Follow best practices to identify and manage treatment-related adverse events in patients with lung cancer receiving ADC-based therapies with the entire care team to improve outcomes and quality of life.
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Benjamin Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley
Memorial Hospital
Medical Director, Thoracic Oncology Program, SKCC at Sibley
Washington, District of Columbia
Benjamin Levy, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi
Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health;
Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; and Pfizer.
Faculty/Planner
Marina Chiara Garassino, MD
Professor of Medicine
Director, Thoracic Oncology Program
University of Chicago Medicine
Hematology-Oncology
Chicago, Illinois
Marina Chiara Garassino, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb;
Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead
Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD
International GmbH; Novartis Pharmaceuticals Corporation; OSE
Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics,
Inc.; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from Research funding to institution for
AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche
Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme
Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer;
Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation;
Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.;
Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis
Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and
Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.
Faculty/Planner
Stephen V. Liu, MD
Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia
Stephen V. Liu, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca;
Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst
Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology,
Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.;
Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.;
Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company
Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation
Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck &
Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and
Turning Point Therapeutics, Inc.
Faculty/Planner
Zosia Piotrowska, MD
Assistant Professor of Medicine, Harvard Medical School
Assistant in Medicine, Massachusetts General Hospital
Boston, Massachusetts
Zosia Piotrowska, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation;
Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH;
Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co.,
Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint
Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum
Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro,
Inc./GlaxoSmithKline.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 23, 2025; credit is no longer available.
Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer
Media: Enduring Material
Activity Release Date: February 24, 2024
Activity Expiration Date: March 23, 2025
Time to Complete Activity: 60 minutes
Activity Description
Antibody-drug conjugates (ADCs) represent an exciting frontier in the
realm of precision lung cancer care, bringing hope to patients with limited
treatment options. The promise of these agents is now transitioning from
research settings to real-world practice, but many questions remain to be
answered by ongoing studies. In addition to the first HER2-targeting ADC
approved for HER2-mutated NSCLC, various other potent ADCs, such as those
targeting HER3, TROP2, B7-H3, among many others, are showing promising
activity in clinical trials, either as monotherapies or as integral parts of
combinations, spanning different settings and patient populations.
This unique educational activity, based on a recent live symposium, features
entertaining quiz-based Peer Pressure Challenges during which top experts are
put on the spot to compete against each other and test their knowledge about
ADCs. These game show segments are combined with related mini-lectures and
open discussion forums to review key concepts related to the ADCs, analyze
the latest evidence, examine unique nuances of using these therapies in
real-world practice, and explore the challenging issues and burning questions
about how to maximize the potential of ADCs in lung cancer.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other multidisciplinary and interprofessional healthcare providers involved in the care of patients with lung cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the clinical importance and biologic rationale for the use of different ADC-based approaches in lung cancer.
- Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of various ADCs in lung cancer.
- Integrate ADCs into treatment plans of carefully selected patients with lung cancer.
- Follow best practices to identify and manage treatment-related adverse events in patients with lung cancer receiving ADC-based therapies with the entire care team to improve outcomes and quality of life.
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Benjamin Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley
Memorial Hospital
Medical Director, Thoracic Oncology Program, SKCC at Sibley
Washington, District of Columbia
Benjamin Levy, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi
Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health;
Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; and Pfizer.
Faculty/Planner
Marina Chiara Garassino, MD
Professor of Medicine
Director, Thoracic Oncology Program
University of Chicago Medicine
Hematology-Oncology
Chicago, Illinois
Marina Chiara Garassino, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb;
Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead
Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD
International GmbH; Novartis Pharmaceuticals Corporation; OSE
Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics,
Inc.; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from Research funding to institution for
AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche
Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme
Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer;
Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation;
Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.;
Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis
Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and
Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.
Faculty/Planner
Stephen V. Liu, MD
Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia
Stephen V. Liu, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca;
Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst
Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology,
Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.;
Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.;
Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company
Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation
Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck &
Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and
Turning Point Therapeutics, Inc.
Faculty/Planner
Zosia Piotrowska, MD
Assistant Professor of Medicine, Harvard Medical School
Assistant in Medicine, Massachusetts General Hospital
Boston, Massachusetts
Zosia Piotrowska, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation;
Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH;
Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co.,
Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint
Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum
Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro,
Inc./GlaxoSmithKline.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
StartThis activity expired on March 23, 2025; credit is no longer available.
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
Media: Enduring Material
Activity Release Date: February 24, 2024
Activity Expiration Date: March 23, 2025
Time to Complete Activity: 60 minutes
Activity Description
In recent years, there have been notable advances in the treatment of
small-cell lung cancer (SCLC). Several new options have now become
guideline-recommended standards of care. Despite these advancements, the
prognosis for SCLC remains poor. This justifies efforts to optimize and
expand the use of approved treatments and explore novel therapies with
different mechanisms of action. Several potential therapeutic strategies are
currently under examination in clinical trials that will hopefully lead to a
further expansion of the SCLC treatment arsenal.
In this PeerView educational activity, based on a recent live symposium, experts discuss the latest evidence, ongoing trials, clinical cases, and challenging questions to take a deeper dive into the nuances of how to optimally integrate the latest therapeutic advances into clinical practice. The faculty panel provides evidence-based and practical guidance to help the lung cancer care team better understand the current and evolving treatment arsenal for SCLC and improve the care and outcomes of patients with SCLC.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other clinicians involved in the management of SCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Analyze the role and use of current and emerging therapies for SCLC, and the evidence that supports their use
- Incorporate current standard-of-care therapies into individualized treatment plans for patients with SCLC based on the latest evidence, guideline recommendations, and patient needs and preferences
- Recommend enrollment in clinical trials to eligible patients who could benefit from the current and emerging therapies
- Implement multidisciplinary/interprofessional strategies and shared decision-making to ensure optimal care, including effective management of AEs, throughout the disease continuum for each patient with SCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD
Executive Director, Marlene and Stewart Greenebaum Comprehensive Cancer
Center
Marlene and Stewart Greenebaum Professor in Oncology
Senior Associate Dean of Cancer Programs, University of Maryland School of
Medicine
Associate Vice President for Cancer Programs, University of Maryland,
Baltimore
Chief of Service, University of Maryland Medical Center
Baltimore, Maryland
Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.;
AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co.,
Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb;
Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.;
GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis
Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma
Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda
Pharmaceutical Company Limited.
Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer
Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi
Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.;
GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics,
Inc.; and Y-mAbs Therapeutics, Inc.
Faculty/Planner
Anne Chiang, MD, PhD, FASCO
Associate Professor of Medicine
Associate Yale Cancer Center Director, Clinical Initiatives
Yale University School of Medicine
New Haven, Connecticut
Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.;
Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie, Inc.; Amgen Inc.;
AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech,
Inc.
Faculty/Planner
Jared Weiss, MD
Professor of Medicine
Section Chief of Thoracic and Head/Neck Oncology
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Jared Weiss, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.;
AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab
A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly;
Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.
Grant/Research Support from G1 Therapeutics, Inc.; Inspirna,
Inc.; and Lilly.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 23, 2025; credit is no longer available.
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
Media: Enduring Material
Activity Release Date: February 24, 2024
Activity Expiration Date: March 23, 2025
Time to Complete Activity: 60 minutes
Activity Description
In recent years, there have been notable advances in the treatment of
small-cell lung cancer (SCLC). Several new options have now become
guideline-recommended standards of care. Despite these advancements, the
prognosis for SCLC remains poor. This justifies efforts to optimize and
expand the use of approved treatments and explore novel therapies with
different mechanisms of action. Several potential therapeutic strategies are
currently under examination in clinical trials that will hopefully lead to a
further expansion of the SCLC treatment arsenal.
In this PeerView educational activity, based on a recent live symposium, experts discuss the latest evidence, ongoing trials, clinical cases, and challenging questions to take a deeper dive into the nuances of how to optimally integrate the latest therapeutic advances into clinical practice. The faculty panel provides evidence-based and practical guidance to help the lung cancer care team better understand the current and evolving treatment arsenal for SCLC and improve the care and outcomes of patients with SCLC.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other clinicians involved in the management of SCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Analyze the role and use of current and emerging therapies for SCLC, and the evidence that supports their use
- Incorporate current standard-of-care therapies into individualized treatment plans for patients with SCLC based on the latest evidence, guideline recommendations, and patient needs and preferences
- Recommend enrollment in clinical trials to eligible patients who could benefit from the current and emerging therapies
- Implement multidisciplinary/interprofessional strategies and shared decision-making to ensure optimal care, including effective management of AEs, throughout the disease continuum for each patient with SCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD
Executive Director, Marlene and Stewart Greenebaum Comprehensive Cancer
Center
Marlene and Stewart Greenebaum Professor in Oncology
Senior Associate Dean of Cancer Programs, University of Maryland School of
Medicine
Associate Vice President for Cancer Programs, University of Maryland,
Baltimore
Chief of Service, University of Maryland Medical Center
Baltimore, Maryland
Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.;
AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co.,
Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb;
Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.;
GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis
Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma
Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda
Pharmaceutical Company Limited.
Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer
Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi
Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.;
GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics,
Inc.; and Y-mAbs Therapeutics, Inc.
Faculty/Planner
Anne Chiang, MD, PhD, FASCO
Associate Professor of Medicine
Associate Yale Cancer Center Director, Clinical Initiatives
Yale University School of Medicine
New Haven, Connecticut
Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.;
Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie, Inc.; Amgen Inc.;
AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech,
Inc.
Faculty/Planner
Jared Weiss, MD
Professor of Medicine
Section Chief of Thoracic and Head/Neck Oncology
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Jared Weiss, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.;
AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab
A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly;
Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.
Grant/Research Support from G1 Therapeutics, Inc.; Inspirna,
Inc.; and Lilly.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity
StartThis activity expired on March 20, 2025; credit is no longer available.
Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity
Media: Enduring Material
Activity Release Date: February 21, 2024
Activity Expiration Date: March 20, 2025
Time to Complete Activity: 60 minutes
Activity Description
Multiple EGFR-targeted therapies have become available for patients with
NSCLC harboring common and uncommon EGFR mutations, and novel
options and combinations with practice-changing potential have shown great
promise in clinical trials. How can healthcare providers make sense of the
increasing complexity in the evidence base and best select and sequence the
current and emerging therapy options?
In this PeerView educational activity, based on a recent live symposium, expert panelists provide guidance on appropriate biomarker testing, discuss the expanding landscape of targeted therapy options, and explore the nuances of making precision decisions for patients with EGFR-mutated NSCLC.
Target Audience
This activity has been designed to meet the educational needs of thoracic oncologists, medical oncologists, advanced practice clinicians, and other clinicians involved in the management of patients with lung cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the evolving role of EGFR mutations and co-occurring genomic alterations in guiding decision-making and treatment selection for patients with NSCLC
- Apply broad NGS-based testing to identify therapeutically actionable alterations, including EGFR mutations, and potential resistance mechanisms
- Integrate biomarker findings, clinical trial evidence, and shared decision-making strategies to personalize treatment planning in EGFRm NSCLC settings
- Construct team-based strategies to ensure individualized care throughout the course of treatment, including patient/caregiver education and engagement, and optimal approaches to facilitate shared decision-making in EGFRm NSCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joshua Sabari, MD
Assistant Professor of Medicine
NYU Langone Health
Perlmutter Cancer Center
New York, New York
Joshua Sabari, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca;
Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron
Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals,
Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron
Pharmaceuticals Inc.
Faculty/Planner
Jyoti D. Patel, MD
Professor of Medicine
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Lurie Cancer Center
Associate Vice Chair of Clinical Research
Department of Medicine
Northwestern University, Feinberg School of Medicine
Chicago, Illinois
Jyoti D. Patel, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics;
AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.;
Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda
Pharmaceutical Company Limited.
Other Financial or Material Support for Travel from Daiichi
Sankyo, Inc. and Tempus.
Faculty/Planner
Alexander I. Spira, MD, PhD, FACP
Co Director Virginia Cancer Specialists Research Institute
Director, NEXT Oncology Virginia
Co Chair, US Oncology Thoracic Research Program
Fairfax, Virginia
Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.;
AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines
Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte;
Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals,
Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics,
Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.;
Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.;
Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas
Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond
Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer
Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics,
Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio,
Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo
Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics;
Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals
Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines,
Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda
Pharmaceutical Company Limited.
Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol
Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck
& Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical
Company Limited.
Stock Shareholder in Lilly.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/20/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 20, 2025; credit is no longer available.
Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity
Media: Enduring Material
Activity Release Date: February 21, 2024
Activity Expiration Date: March 20, 2025
Time to Complete Activity: 60 minutes
Activity Description
Multiple EGFR-targeted therapies have become available for patients with
NSCLC harboring common and uncommon EGFR mutations, and novel
options and combinations with practice-changing potential have shown great
promise in clinical trials. How can healthcare providers make sense of the
increasing complexity in the evidence base and best select and sequence the
current and emerging therapy options?
In this PeerView educational activity, based on a recent live symposium, expert panelists provide guidance on appropriate biomarker testing, discuss the expanding landscape of targeted therapy options, and explore the nuances of making precision decisions for patients with EGFR-mutated NSCLC.
Target Audience
This activity has been designed to meet the educational needs of thoracic oncologists, medical oncologists, advanced practice clinicians, and other clinicians involved in the management of patients with lung cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the evolving role of EGFR mutations and co-occurring genomic alterations in guiding decision-making and treatment selection for patients with NSCLC
- Apply broad NGS-based testing to identify therapeutically actionable alterations, including EGFR mutations, and potential resistance mechanisms
- Integrate biomarker findings, clinical trial evidence, and shared decision-making strategies to personalize treatment planning in EGFRm NSCLC settings
- Construct team-based strategies to ensure individualized care throughout the course of treatment, including patient/caregiver education and engagement, and optimal approaches to facilitate shared decision-making in EGFRm NSCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joshua Sabari, MD
Assistant Professor of Medicine
NYU Langone Health
Perlmutter Cancer Center
New York, New York
Joshua Sabari, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca;
Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron
Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals,
Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron
Pharmaceuticals Inc.
Faculty/Planner
Jyoti D. Patel, MD
Professor of Medicine
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Lurie Cancer Center
Associate Vice Chair of Clinical Research
Department of Medicine
Northwestern University, Feinberg School of Medicine
Chicago, Illinois
Jyoti D. Patel, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics;
AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.;
Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda
Pharmaceutical Company Limited.
Other Financial or Material Support for Travel from Daiichi
Sankyo, Inc. and Tempus.
Faculty/Planner
Alexander I. Spira, MD, PhD, FACP
Co Director Virginia Cancer Specialists Research Institute
Director, NEXT Oncology Virginia
Co Chair, US Oncology Thoracic Research Program
Fairfax, Virginia
Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.;
AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines
Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte;
Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals,
Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics,
Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.;
Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.;
Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas
Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond
Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer
Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics,
Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio,
Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo
Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics;
Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals
Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines,
Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda
Pharmaceutical Company Limited.
Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol
Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck
& Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical
Company Limited.
Stock Shareholder in Lilly.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/20/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care
StartThis activity expired on February 6, 2025; credit is no longer available.
Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care
Media: Enduring Material
Activity Release Date: February 7, 2024
Activity Expiration Date: February 6, 2025
Time to Complete Activity: 60 minutes
Activity Description
Bullous pemphigoid (BP) is a rare autoimmune subepidermal blistering
disease characterized by large, tense blisters in the skin preceded by
urticarial plaques and pruritus. It occurs most frequently in elderly
patients, with risk rising exponentially after the age of 80. Diagnosis is
often missed or delayed, partly due to it being a rare disorder, and partly
due to atypical presentations or similarities with other skin
conditions.
Although management guidelines have been updated there is still a lack of
consensus on optimal treatment regimens and duration. Systemic
corticosteroids and other immunosuppressive agents carry risks of adverse
events; thus, targeted agents that are already approved for other diseases
are under study for their utility in BP.
In order to help dermatologists and other clinicians treating patients with
BP remain updated on advances in treatment, PeerView has prepared this
discussion between two expert dermatologists. Learners will hear about the
impact of BP on patient quality of life and how to differentiate BP from
other skin conditions, as well as how to treat patients using the latest
guidelines and targeted therapy.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
- Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
- Select and monitor treatment for patients with BP according to updated guidelines
- Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska
Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana
David Rosmarin, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio,
Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals,
Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen
Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals
Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo
Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries,
Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers
Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals
Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene
Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.;
Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals
Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/6/2025. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 6, 2025; credit is no longer available.
Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care
Media: Enduring Material
Activity Release Date: February 7, 2024
Activity Expiration Date: February 6, 2025
Time to Complete Activity: 60 minutes
Activity Description
Bullous pemphigoid (BP) is a rare autoimmune subepidermal blistering
disease characterized by large, tense blisters in the skin preceded by
urticarial plaques and pruritus. It occurs most frequently in elderly
patients, with risk rising exponentially after the age of 80. Diagnosis is
often missed or delayed, partly due to it being a rare disorder, and partly
due to atypical presentations or similarities with other skin
conditions.
Although management guidelines have been updated there is still a lack of
consensus on optimal treatment regimens and duration. Systemic
corticosteroids and other immunosuppressive agents carry risks of adverse
events; thus, targeted agents that are already approved for other diseases
are under study for their utility in BP.
In order to help dermatologists and other clinicians treating patients with
BP remain updated on advances in treatment, PeerView has prepared this
discussion between two expert dermatologists. Learners will hear about the
impact of BP on patient quality of life and how to differentiate BP from
other skin conditions, as well as how to treat patients using the latest
guidelines and targeted therapy.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
- Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
- Select and monitor treatment for patients with BP according to updated guidelines
- Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska
Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana
David Rosmarin, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio,
Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals,
Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen
Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals
Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo
Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries,
Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers
Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals
Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene
Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.;
Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals
Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/6/2025. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
StartThis activity expired on February 26, 2025; credit is no longer available.
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 45 minutes
Activity Description
Developments in treatment options for hepatocellular carcinoma (HCC),
namely immune-based strategies, have enhanced outcomes across the disease
continuum. To effectively integrate these modern regimens into practice,
close collaboration among interventional radiologists (IR), medical
oncologists, and the wider care team are critical. In this Clinical Consults
activity, the expert faculty panel discuss patient scenarios illustrating
real-world applications of current and emerging data and provide guidance on
topics such as selecting and sequencing treatment over the course of disease,
delivering personalized care when integrating immunotherapy platforms, and
anticipating and managing safety/toxicity considerations.
This activity unravels the latest data on innovative
immunotherapy and locoregional therapy combinations in intermediate-stage
disease and the transition to systemic therapy in advanced disease. Join
today to learn what the experts have to say for synergizing success in
HCC!
Target Audience
This activity has been designed to meet the educational needs of interventional radiologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the latest safety/efficacy evidence and guideline recommendations supporting clinical applications of immunotherapy regimens for the management of early-, intermediate-, and advanced-stage HCC
- Formulate personalized treatment plans with immunotherapy platforms for the management of HCC based on current and emerging clinical evidence, guideline recommendations, and expert guidance
- Apply team-based strategies to address practical aspects of care when integrating immunotherapy platforms, including managing immune-related adverse events, dosing considerations, care coordination across specialties, and patient/caregiver education
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lipika Goyal, MD, MPhil
Director of Gastrointestinal Oncology
Associate Professor of Medicine
Division of Oncology
Stanford School of Medicine
Palo Alto, California
Lipika Goyal, MD, MPhil, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alentis Therapeutics AG;
Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines
Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.;
Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED
Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical
Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera
Biosciences.
Data Safety Monitoring Board for AstraZeneca.
Co-Chair/Planner
Riad Salem, MD, MBA
Professor of Radiology, Medicine, and Surgery
Chief, Section of Vascular and Interventional Radiology
Vice-Chairman, Image-Guided Therapy
Department of Radiology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Riad Salem, MD, MBA, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bard
Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai
Inc./Merck & Co., Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from AstraZeneca.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 26, 2025; credit is no longer available.
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 45 minutes
Activity Description
Developments in treatment options for hepatocellular carcinoma (HCC),
namely immune-based strategies, have enhanced outcomes across the disease
continuum. To effectively integrate these modern regimens into practice,
close collaboration among interventional radiologists (IR), medical
oncologists, and the wider care team are critical. In this Clinical Consults
activity, the expert faculty panel discuss patient scenarios illustrating
real-world applications of current and emerging data and provide guidance on
topics such as selecting and sequencing treatment over the course of disease,
delivering personalized care when integrating immunotherapy platforms, and
anticipating and managing safety/toxicity considerations.
This activity unravels the latest data on innovative
immunotherapy and locoregional therapy combinations in intermediate-stage
disease and the transition to systemic therapy in advanced disease. Join
today to learn what the experts have to say for synergizing success in
HCC!
Target Audience
This activity has been designed to meet the educational needs of interventional radiologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the latest safety/efficacy evidence and guideline recommendations supporting clinical applications of immunotherapy regimens for the management of early-, intermediate-, and advanced-stage HCC
- Formulate personalized treatment plans with immunotherapy platforms for the management of HCC based on current and emerging clinical evidence, guideline recommendations, and expert guidance
- Apply team-based strategies to address practical aspects of care when integrating immunotherapy platforms, including managing immune-related adverse events, dosing considerations, care coordination across specialties, and patient/caregiver education
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lipika Goyal, MD, MPhil
Director of Gastrointestinal Oncology
Associate Professor of Medicine
Division of Oncology
Stanford School of Medicine
Palo Alto, California
Lipika Goyal, MD, MPhil, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alentis Therapeutics AG;
Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines
Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.;
Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED
Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical
Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera
Biosciences.
Data Safety Monitoring Board for AstraZeneca.
Co-Chair/Planner
Riad Salem, MD, MBA
Professor of Radiology, Medicine, and Surgery
Chief, Section of Vascular and Interventional Radiology
Vice-Chairman, Image-Guided Therapy
Department of Radiology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Riad Salem, MD, MBA, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Bard
Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai
Inc./Merck & Co., Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from AstraZeneca.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum
StartThis activity expired on February 26, 2025; credit is no longer available.
Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum
Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 90 minutes
Activity Description
Which treatment advances are making an impact for patients with bladder cancer? Approved and emerging therapeutic strategies that include immune checkpoint inhibitors, antibody–drug conjugates (ADCs) and other classes of agents are changing outcomes for patients with locally advanced or metastatic disease, while those with earlier-stage disease, including non-muscle invasive bladder cancer (NMIBC) or high-risk muscle-invasive bladder cancer (MIBC), are benefiting from bladder-sparing and perioperative approaches. Join PeerView and the Bladder Cancer Advocacy Network (BCAN) to learn how these treatment advances translate into practice, as clinical decision points are brought to life through discussion of real-world patient cases. Featuring a panel of experts, as well as resources and tools from BCAN, this activity offers learners practical guidance on incorporating the latest data on a variety of therapeutic strategies into the development of personalized treatment plans for patients throughout the disease continuum, creating team-based protocols for managing adverse events, and addressing inequities in diagnosis and treatment to increase access to state-of-the-art care for all patients.
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of bladder cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current data on therapeutic strategies based on innovative drug delivery techniques, targeted agents, and modern immunotherapy regimens for the treatment of bladder cancer
- Integrate approved and emerging therapeutic approaches into personalized treatment plans for patients with various stages of bladder cancer, considering evidence, guidelines, and principles of team-based and patient-centered care
- Implement evidence- and team-based management protocols to address the suite of adverse events associated with bladder cancer therapies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York
Matthew D. Galsky, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle
Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD
Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly;
Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co.,
Inc.
Faculty/Planner
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine of CWRU
Director, Genitourinary Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Shilpa Gupta, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.;
Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics
(Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.;
Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.;
and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle
Genetics (Seagen Inc.).
Faculty/Planner
Andrea Necchi, MD
Associate Professor, Vita-Salute San Raffaele University
Director of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital
Milan, Italy
Andrea Necchi, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca;
Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences,
Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen
Inc.
Grant/Research Support from Bristol Myers Squibb; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co.,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 26, 2025; credit is no longer available.
Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum
Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 90 minutes
Activity Description
Which treatment advances are making an impact for patients with bladder cancer? Approved and emerging therapeutic strategies that include immune checkpoint inhibitors, antibody–drug conjugates (ADCs) and other classes of agents are changing outcomes for patients with locally advanced or metastatic disease, while those with earlier-stage disease, including non-muscle invasive bladder cancer (NMIBC) or high-risk muscle-invasive bladder cancer (MIBC), are benefiting from bladder-sparing and perioperative approaches. Join PeerView and the Bladder Cancer Advocacy Network (BCAN) to learn how these treatment advances translate into practice, as clinical decision points are brought to life through discussion of real-world patient cases. Featuring a panel of experts, as well as resources and tools from BCAN, this activity offers learners practical guidance on incorporating the latest data on a variety of therapeutic strategies into the development of personalized treatment plans for patients throughout the disease continuum, creating team-based protocols for managing adverse events, and addressing inequities in diagnosis and treatment to increase access to state-of-the-art care for all patients.
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of bladder cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current data on therapeutic strategies based on innovative drug delivery techniques, targeted agents, and modern immunotherapy regimens for the treatment of bladder cancer
- Integrate approved and emerging therapeutic approaches into personalized treatment plans for patients with various stages of bladder cancer, considering evidence, guidelines, and principles of team-based and patient-centered care
- Implement evidence- and team-based management protocols to address the suite of adverse events associated with bladder cancer therapies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York
Matthew D. Galsky, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle
Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD
Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly;
Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co.,
Inc.
Faculty/Planner
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine of CWRU
Director, Genitourinary Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Shilpa Gupta, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.;
Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics
(Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.;
Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.;
and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle
Genetics (Seagen Inc.).
Faculty/Planner
Andrea Necchi, MD
Associate Professor, Vita-Salute San Raffaele University
Director of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital
Milan, Italy
Andrea Necchi, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca;
Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences,
Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen
Inc.
Grant/Research Support from Bristol Myers Squibb; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co.,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies
StartThis activity expired on February 25, 2025; credit is no longer available.
Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes
Activity Description
Are you up for the challenge of modern treatment of prostate cancer? As
the therapeutic landscape for localized and advanced prostate cancer has
expanded greatly within the past few years, care team clinicians have a
variety of options available or on the horizon for use in personalized care
across the disease continuum. Approvals and positive results for high-risk
biochemically recurrent localized disease and treatment intensification
strategies for advanced disease with various regimens that include
AR-targeting agents, PARP inhibitors, modern radioligands, CDK4/6 inhibitors,
and IO + TKI combinations are set to further improve patient care.
Join PeerView and ZERO Prostate Cancer for a lively activity that includes
friendly competition among a panel of experts that competes to answer
questions on prostate cancer treatment while providing insight on evidence
supporting the use of a variety of prostate cancer therapeutics and
strategies for personalized treatment selection, including genetic and
molecular testing, and increasing access to optimal care.
Target Audience
This activity has been designed to meet the educational needs of urologic and medical oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of prostate cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale and clinical data supporting contemporary treatment options, including the need for germline and somatic testing, that can inform personalized treatment selection for patients with prostate cancer
- Design personalized team-based treatment protocols that incorporate key evidence-based strategies pertaining to approved and emerging therapeutics for patients with prostate cancer, including in the context of a clinical trial
- Manage treatment-related adverse events from personalized treatment plans for patients with prostate cancer to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia
Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer
Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen
Inc.; and Tavanta Therapeutics.
Faculty/Planner
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Alicia K. Morgans, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Advanced Accelerator Applications
(AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.;
Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix
Pharmaceuticals Limited.
Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation;
Myovant Sciences Ltd.; Pfizer; and Sanofi.
Faculty/Planner
Neal D. Shore, MD, FACS
Medical Director, Carolina Urologic Research Center
Myrtle Beach, South Carolina
Neal D. Shore, MD, FACS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa
Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris
Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.;
Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol
Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc;
Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche
Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation
Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae
Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck &
Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics,
Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox
Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.;
Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical;
Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi
Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar
Pharmaceuticals, Inc.; and UroGen Pharma, Inc.
Faculty/Planner
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Matthew R. Smith, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer
Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 25, 2025; credit is no longer available.
Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes
Activity Description
Are you up for the challenge of modern treatment of prostate cancer? As
the therapeutic landscape for localized and advanced prostate cancer has
expanded greatly within the past few years, care team clinicians have a
variety of options available or on the horizon for use in personalized care
across the disease continuum. Approvals and positive results for high-risk
biochemically recurrent localized disease and treatment intensification
strategies for advanced disease with various regimens that include
AR-targeting agents, PARP inhibitors, modern radioligands, CDK4/6 inhibitors,
and IO + TKI combinations are set to further improve patient care.
Join PeerView and ZERO Prostate Cancer for a lively activity that includes
friendly competition among a panel of experts that competes to answer
questions on prostate cancer treatment while providing insight on evidence
supporting the use of a variety of prostate cancer therapeutics and
strategies for personalized treatment selection, including genetic and
molecular testing, and increasing access to optimal care.
Target Audience
This activity has been designed to meet the educational needs of urologic and medical oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of prostate cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale and clinical data supporting contemporary treatment options, including the need for germline and somatic testing, that can inform personalized treatment selection for patients with prostate cancer
- Design personalized team-based treatment protocols that incorporate key evidence-based strategies pertaining to approved and emerging therapeutics for patients with prostate cancer, including in the context of a clinical trial
- Manage treatment-related adverse events from personalized treatment plans for patients with prostate cancer to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia
Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer
Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen
Inc.; and Tavanta Therapeutics.
Faculty/Planner
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Alicia K. Morgans, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Advanced Accelerator Applications
(AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.;
Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix
Pharmaceuticals Limited.
Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation;
Myovant Sciences Ltd.; Pfizer; and Sanofi.
Faculty/Planner
Neal D. Shore, MD, FACS
Medical Director, Carolina Urologic Research Center
Myrtle Beach, South Carolina
Neal D. Shore, MD, FACS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa
Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris
Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.;
Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol
Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc;
Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche
Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation
Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae
Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck &
Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics,
Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox
Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.;
Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical;
Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi
Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar
Pharmaceuticals, Inc.; and UroGen Pharma, Inc.
Faculty/Planner
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Matthew R. Smith, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer
Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies
StartThis activity expired on February 25, 2025; credit is no longer available.
Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes
Activity Description
The rapid expansion in the renal cell carcinoma (RCC) therapeutic
landscape has brought new hope for patients with kidney cancer along with
increasing opportunities for healthcare professionals to provide personalized
care across the disease spectrum. With FDA approvals of TKIs and immune
checkpoint inhibitors in various disease settings, frontline treatment
options include dual immunotherapy and IO plus TKI regimens, with some of
these combinations showing benefit in patients with non–clear cell RCC, a
population with limited clinical data and poor treatment outcomes. Critical
therapeutic options are emerging in the perioperative setting, and further
impact has been made in the refractory setting for patients who have been
heavily pretreated.
Join PeerView and the Kidney Cancer Research Alliance (KCCure)
for an activity that features expert insights on the latest clinical trial
and real-world evidence along with guidance on how to integrate scientific
advances into modern RCC practice. Learn strategies for selecting and
sequencing treatments, mitigating and managing adverse events, and
incorporating shared decision-making into comprehensive, team-based care.
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the management of RCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Review evidence on treatment efficacy and safety of approved and emerging therapeutic options for patients with RCC across different disease stages and histologic subtypes
- Design individualized treatment plans based on current evidence, as well as patient-, disease-, and treatment-specific factors for patients with RCC
- Develop team-based approaches to anticipate, mitigate, and manage adverse events associated with treatments for patients with RCC to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Sumanta Kumar Pal, MD, FASCO
Professor, Department of Medical Oncology & Therapeutics
Research
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California
Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from Allogene Therapeutics;
CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F.
Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.
Faculty/Planner
Pedro C. Barata, MD, MSc, FACP
Co-Leader Genitourinary (GU) Disease Team
Director of GU Medical Oncology Research Program
University Hospitals Seidman Cancer Center
Associate Professor of Medicine
Case Western Reserve University
Case Comprehensive Cancer Center
Cleveland, Ohio
Pedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.;
AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono;
Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and
Sanofi.
Grant/Research Support from EMD Serono and Exelixis,
Inc.
Speakers Bureau participant with Bayer Corporation;
Caris Life Sciences; Merck & Co., Inc.; and Sanofi.
Faculty/Planner
David F. McDermott, MD
Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer
Program
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Tian Zhang, MD, MHS
Associate Professor, Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas
Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Aravive; AstraZeneca;
AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris
Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences,
Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.
Grant/Research Support from ALX Oncology; Janssen
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.
Other Financial or Material Support for leadership or
fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee;
Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and
National Cancer Institute (NCI) Steering Renal Task Force.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 25, 2025; credit is no longer available.
Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes
Activity Description
The rapid expansion in the renal cell carcinoma (RCC) therapeutic
landscape has brought new hope for patients with kidney cancer along with
increasing opportunities for healthcare professionals to provide personalized
care across the disease spectrum. With FDA approvals of TKIs and immune
checkpoint inhibitors in various disease settings, frontline treatment
options include dual immunotherapy and IO plus TKI regimens, with some of
these combinations showing benefit in patients with non–clear cell RCC, a
population with limited clinical data and poor treatment outcomes. Critical
therapeutic options are emerging in the perioperative setting, and further
impact has been made in the refractory setting for patients who have been
heavily pretreated.
Join PeerView and the Kidney Cancer Research Alliance (KCCure)
for an activity that features expert insights on the latest clinical trial
and real-world evidence along with guidance on how to integrate scientific
advances into modern RCC practice. Learn strategies for selecting and
sequencing treatments, mitigating and managing adverse events, and
incorporating shared decision-making into comprehensive, team-based care.
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the management of RCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Review evidence on treatment efficacy and safety of approved and emerging therapeutic options for patients with RCC across different disease stages and histologic subtypes
- Design individualized treatment plans based on current evidence, as well as patient-, disease-, and treatment-specific factors for patients with RCC
- Develop team-based approaches to anticipate, mitigate, and manage adverse events associated with treatments for patients with RCC to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Sumanta Kumar Pal, MD, FASCO
Professor, Department of Medical Oncology & Therapeutics
Research
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California
Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from Allogene Therapeutics;
CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F.
Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.
Faculty/Planner
Pedro C. Barata, MD, MSc, FACP
Co-Leader Genitourinary (GU) Disease Team
Director of GU Medical Oncology Research Program
University Hospitals Seidman Cancer Center
Associate Professor of Medicine
Case Western Reserve University
Case Comprehensive Cancer Center
Cleveland, Ohio
Pedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.;
AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono;
Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and
Sanofi.
Grant/Research Support from EMD Serono and Exelixis,
Inc.
Speakers Bureau participant with Bayer Corporation;
Caris Life Sciences; Merck & Co., Inc.; and Sanofi.
Faculty/Planner
David F. McDermott, MD
Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer
Program
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Tian Zhang, MD, MHS
Associate Professor, Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas
Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Aravive; AstraZeneca;
AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris
Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences,
Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.
Grant/Research Support from ALX Oncology; Janssen
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.
Other Financial or Material Support for leadership or
fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee;
Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and
National Cancer Institute (NCI) Steering Renal Task Force.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer
StartThis activity expired on January 25, 2025; credit is no longer available.
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: January 25, 2025
Time to Complete Activity: 60 minutes
Activity Description
In this activity, Dr. Aditya Bardia reviews the latest evidence for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer (EBC) and discusses how these agents can reduce the risk of recurrence and improve outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the care of patients with HR+/HER- EBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Formulate individualized treatment plans inclusive of adjuvant CDK4/6 inhibitors and ET for patients with HR+/HER2- EBC based on latest evidence and recommendations
- Develop a team-based plan for patients with EBC undergoing adjuvant systemic therapy to closely monitor them, diagnose and manage AEs, and achieve optimal treatment adherence and persistence
- Implement strategies to recognize and address disparities in breast cancer for diverse racial and ethnic groups, with a goal of eliminating barriers and ensuring optimal care for all patients, especially minority populations in community settings
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Medical Oncology Division
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California
Aditya Bardia, MD, MPH, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo
Inc./AstraZeneca; Foundation Medicine, Inc.; Genentech, Inc.; Immunomedics,
Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Phillips Healthcare Corporation;
Radius Health, Inc.; and Sanofi.
Grant/Research Support from Daiichi Sankyo
Inc./AstraZeneca; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences,
Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Pfizer; Radius Health, Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 25, 2025; credit is no longer available.
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer
Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: January 25, 2025
Time to Complete Activity: 60 minutes
Activity Description
In this activity, Dr. Aditya Bardia reviews the latest evidence for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer (EBC) and discusses how these agents can reduce the risk of recurrence and improve outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the care of patients with HR+/HER- EBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Formulate individualized treatment plans inclusive of adjuvant CDK4/6 inhibitors and ET for patients with HR+/HER2- EBC based on latest evidence and recommendations
- Develop a team-based plan for patients with EBC undergoing adjuvant systemic therapy to closely monitor them, diagnose and manage AEs, and achieve optimal treatment adherence and persistence
- Implement strategies to recognize and address disparities in breast cancer for diverse racial and ethnic groups, with a goal of eliminating barriers and ensuring optimal care for all patients, especially minority populations in community settings
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Medical Oncology Division
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California
Aditya Bardia, MD, MPH, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo
Inc./AstraZeneca; Foundation Medicine, Inc.; Genentech, Inc.; Immunomedics,
Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; Phillips Healthcare Corporation;
Radius Health, Inc.; and Sanofi.
Grant/Research Support from Daiichi Sankyo
Inc./AstraZeneca; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences,
Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Pfizer; Radius Health, Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/25/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes
StartThis activity expired on January 21, 2025; credit is no longer available.
Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes
Media: Enduring Material
Activity Release Date: January 22, 2024
Activity Expiration Date: January 21, 2025
Time to Complete Activity: 60 minutes
Activity Description
Hypertrophic cardiomyopathy (HCM) occurs with an estimated prevalence of
as many as 1 in 200 people, with a mortality rate about 3 times greater
compared with individuals of a similar age without HCM. The clinical course
of HCM can vary greatly depending upon the individual, with some patients
being asymptomatic and others experiencing extreme fatigue, dyspnea, chest
pain, arrhythmias, and stroke. Experiencing symptoms is the most common
reason patients first seek care, but less than half of symptomatic HCM
patients initially seek care from a cardiologist.
In this learning opportunity, a cardiology expert and a primary care expert
sit down to discuss how primary care professionals can participate in the
diagnosis and management of HCM. By the end, learners will have increased
their ability to recognize symptoms of and risk factors for HCM and their
knowledge of screening tools for patients suspected of having HCM. Learners
will also better understand how to manage common comorbidities and how to
participate in follow-up care and monitoring of patients diagnosed with
HCM.
Target Audience
This activity has been designed to meet the educational needs of primary care clinicians including family medicine and internal medicine physicians, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with or at risk for hypertrophic cardiomyopathy (HCM).
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize symptoms and aspects of family history that may indicate risk for HCM or require differential diagnosis through further evaluation or screening
- Evaluate patients suspected of having HCM using tools such as ECG and echocardiography, including referral to specialty care, as appropriate
- Manage the comorbidities commonly associated with HCM (eg, atrial fibrillation, obesity, sleep apnea, and hypertension) in a shared-care model with specialty care providers
- Participate in follow-up care and monitoring of patients diagnosed with HCM, including checking for drug–drug interactions to ensure timely and safe treatment
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for BioMarin; Bristol Myers Squibb;
Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer;
Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.
Faculty/Planner
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Jefferson Health - Abington
Abington, Pennsylvania
Neil Skolnik, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Abbott; Astellas Pharma Inc.;
AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.;
Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk;
Sanofi; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; GSK; and Novo
Nordisk.
Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and
Teva Pharmaceuticals USA, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/21/2025. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 21, 2025; credit is no longer available.
Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes
Media: Enduring Material
Activity Release Date: January 22, 2024
Activity Expiration Date: January 21, 2025
Time to Complete Activity: 60 minutes
Activity Description
Hypertrophic cardiomyopathy (HCM) occurs with an estimated prevalence of
as many as 1 in 200 people, with a mortality rate about 3 times greater
compared with individuals of a similar age without HCM. The clinical course
of HCM can vary greatly depending upon the individual, with some patients
being asymptomatic and others experiencing extreme fatigue, dyspnea, chest
pain, arrhythmias, and stroke. Experiencing symptoms is the most common
reason patients first seek care, but less than half of symptomatic HCM
patients initially seek care from a cardiologist.
In this learning opportunity, a cardiology expert and a primary care expert
sit down to discuss how primary care professionals can participate in the
diagnosis and management of HCM. By the end, learners will have increased
their ability to recognize symptoms of and risk factors for HCM and their
knowledge of screening tools for patients suspected of having HCM. Learners
will also better understand how to manage common comorbidities and how to
participate in follow-up care and monitoring of patients diagnosed with
HCM.
Target Audience
This activity has been designed to meet the educational needs of primary care clinicians including family medicine and internal medicine physicians, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with or at risk for hypertrophic cardiomyopathy (HCM).
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize symptoms and aspects of family history that may indicate risk for HCM or require differential diagnosis through further evaluation or screening
- Evaluate patients suspected of having HCM using tools such as ECG and echocardiography, including referral to specialty care, as appropriate
- Manage the comorbidities commonly associated with HCM (eg, atrial fibrillation, obesity, sleep apnea, and hypertension) in a shared-care model with specialty care providers
- Participate in follow-up care and monitoring of patients diagnosed with HCM, including checking for drug–drug interactions to ensure timely and safe treatment
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for BioMarin; Bristol Myers Squibb;
Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer;
Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.
Faculty/Planner
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Jefferson Health - Abington
Abington, Pennsylvania
Neil Skolnik, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Abbott; Astellas Pharma Inc.;
AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.;
Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk;
Sanofi; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; GSK; and Novo
Nordisk.
Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and
Teva Pharmaceuticals USA, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/21/2025. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches
StartThis activity expired on February 18, 2025; credit is no longer available.
Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
As immunotherapy and targeted platforms transform hepatocellular carcinoma
(HCC) management, it is becoming increasingly important for oncologists to
“calibrate care” across all stages of disease. A recent wave of approved
therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg,
atezolizumab and bevacizumab), dual immunotherapy combinations (ie,
durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been
introduced in the upfront setting. Recent additions to the second-line
setting have delivered improved options for patients with HCC including
multikinase inhibitors (ie, cabozantinib and regorafenib) and immune
checkpoint inhibitors (eg, pembrolizumab and nivolumab). Furthermore,
emerging data on other up-and-coming targeted platforms have shown the
benefit of combining immunotherapy with LRT for BCLC B disease and the
utility of adjuvant immunotherapy in resectable disease.
In collaboration with Blue Faery: The Adrienne Wilson Liver
Cancer Association, this MasterClass & Case Forum event will consist of a
series of concise, foundational lectures that support the utilization of
modern targeted and immunotherapy regimens across all stages of HCC. Each
MasterClass lecture segment will lead into a Case Forum discussion anchored
by real-world cases informed by the evidence. Learn the latest data on
important topics such as multimodal approaches in intermediate-stage HCC,
emerging adjuvant strategies in early-stage HCC, and adverse event
management.
Target Audience
This activity has been designed to meet the educational needs of gastrointestinal oncologists, medical oncologists, and advanced practice clinicians involved in the management of HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current and emerging clinical evidence supporting the integration of immunotherapy and targeted platforms for the management of HCC
- Apply the latest safety/efficacy evidence supporting immunotherapy and targeted agents when developing personalized treatment plans for patients with HCC across all stages of disease
- Leverage the wider GI-oncology care team to address practical aspects of care when integrating modern therapeutic approaches, including patient consultation and treatment-related adverse event management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ghassan Abou-Alfa, MD, MBA
New York, New York
Professor
Memorial Sloan Kettering Cancer Center
Weill Cornell College at Cornell University
Trinity College Dublin
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Autem
Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co.,
Inc.; Merus; Neogene Therapeutics; NewBridge Pharmaceuticals; Novartis
Pharmaceuticals Corporation; Servier Laboratories; Tempus; Vector; and
Yiviva.
Grant/Research Support from Agenus Inc.; Arcus
Biosciences, Inc.; AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio
Therapeutics Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn
Healthcare SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma
Biotechnology, Inc.; QED Therapeutics; and Yiviva.
Faculty/Planner
Anthony El-Khoueiry, MD
Associate Professor of Medicine
Associate Director for Clinical Research
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California
Anthony El-Khoueiry, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Exelixis,
Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.; Qurient;
and Senti Biosciences.
Grant/Research Support from Astex Pharmaceuticals;
AstraZeneca; Auransa Inc.; and Fulgent Pharma.
Faculty/Planner
Ahmed Omar Kaseb, MD, CMQ
John E. and Dorothy J. Harris Professorship in Gastrointestinal
Cancer Research
Member, National Hepatobiliary Task Force, NCI, USA
Tenured Professor and Director, Hepatocellular Carcinoma
Program
Director, MD Anderson HCC SPORE
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb;
Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and
Pfizer.
Grant/Research Support from Bristol Myers Squibb;
Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer; and
Tvardi Therapeutics.
Faculty/Planner
Stacey M. Stein, MD
Associate Professor of Medicine
Assistant Medical Director of the Clinical Trials Office
Leader, Hepatobiliary Program
Yale School of Medicine
New Haven, Connecticut
Stacey M. Stein, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Eisai Inc.;
Exelixis, Inc.; and Genentech, Inc.
Data Safety Monitoring Board for Aethlon Medical,
Inc.and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Planner
Andrea Wilson Woods
President & Founder, Blue Faery
Andrea Wilson Woods has a financial interest/relationship or affiliation
in the form of:
Consultant for AstraZeneca and Humanise Health.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 18, 2025; credit is no longer available.
Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
As immunotherapy and targeted platforms transform hepatocellular carcinoma
(HCC) management, it is becoming increasingly important for oncologists to
“calibrate care” across all stages of disease. A recent wave of approved
therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg,
atezolizumab and bevacizumab), dual immunotherapy combinations (ie,
durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been
introduced in the upfront setting. Recent additions to the second-line
setting have delivered improved options for patients with HCC including
multikinase inhibitors (ie, cabozantinib and regorafenib) and immune
checkpoint inhibitors (eg, pembrolizumab and nivolumab). Furthermore,
emerging data on other up-and-coming targeted platforms have shown the
benefit of combining immunotherapy with LRT for BCLC B disease and the
utility of adjuvant immunotherapy in resectable disease.
In collaboration with Blue Faery: The Adrienne Wilson Liver
Cancer Association, this MasterClass & Case Forum event will consist of a
series of concise, foundational lectures that support the utilization of
modern targeted and immunotherapy regimens across all stages of HCC. Each
MasterClass lecture segment will lead into a Case Forum discussion anchored
by real-world cases informed by the evidence. Learn the latest data on
important topics such as multimodal approaches in intermediate-stage HCC,
emerging adjuvant strategies in early-stage HCC, and adverse event
management.
Target Audience
This activity has been designed to meet the educational needs of gastrointestinal oncologists, medical oncologists, and advanced practice clinicians involved in the management of HCC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current and emerging clinical evidence supporting the integration of immunotherapy and targeted platforms for the management of HCC
- Apply the latest safety/efficacy evidence supporting immunotherapy and targeted agents when developing personalized treatment plans for patients with HCC across all stages of disease
- Leverage the wider GI-oncology care team to address practical aspects of care when integrating modern therapeutic approaches, including patient consultation and treatment-related adverse event management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ghassan Abou-Alfa, MD, MBA
New York, New York
Professor
Memorial Sloan Kettering Cancer Center
Weill Cornell College at Cornell University
Trinity College Dublin
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Autem
Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co.,
Inc.; Merus; Neogene Therapeutics; NewBridge Pharmaceuticals; Novartis
Pharmaceuticals Corporation; Servier Laboratories; Tempus; Vector; and
Yiviva.
Grant/Research Support from Agenus Inc.; Arcus
Biosciences, Inc.; AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio
Therapeutics Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn
Healthcare SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma
Biotechnology, Inc.; QED Therapeutics; and Yiviva.
Faculty/Planner
Anthony El-Khoueiry, MD
Associate Professor of Medicine
Associate Director for Clinical Research
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California
Anthony El-Khoueiry, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Exelixis,
Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.; Qurient;
and Senti Biosciences.
Grant/Research Support from Astex Pharmaceuticals;
AstraZeneca; Auransa Inc.; and Fulgent Pharma.
Faculty/Planner
Ahmed Omar Kaseb, MD, CMQ
John E. and Dorothy J. Harris Professorship in Gastrointestinal
Cancer Research
Member, National Hepatobiliary Task Force, NCI, USA
Tenured Professor and Director, Hepatocellular Carcinoma
Program
Director, MD Anderson HCC SPORE
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb;
Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and
Pfizer.
Grant/Research Support from Bristol Myers Squibb;
Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer; and
Tvardi Therapeutics.
Faculty/Planner
Stacey M. Stein, MD
Associate Professor of Medicine
Assistant Medical Director of the Clinical Trials Office
Leader, Hepatobiliary Program
Yale School of Medicine
New Haven, Connecticut
Stacey M. Stein, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AstraZeneca; Eisai Inc.;
Exelixis, Inc.; and Genentech, Inc.
Data Safety Monitoring Board for Aethlon Medical,
Inc.and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Planner
Andrea Wilson Woods
President & Founder, Blue Faery
Andrea Wilson Woods has a financial interest/relationship or affiliation
in the form of:
Consultant for AstraZeneca and Humanise Health.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
StartThis activity expired on February 18, 2025; credit is no longer available.
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
Groundbreaking science in personalized therapeutic approaches for advanced
biliary tract cancers (BTCs) has resulted in the expansion of a diverse
management model, empowering oncologists to battle the disease, as emerging
evidence continues to reshape treatment planning based on patient-specific
findings. These developments have led to the approval of several immune-based
and molecularly targeted therapies for the clinical management of advanced
BTCs. Through a case-based discussion, experts will provide valuable insight
on the practical aspects of integrating these new and emerging therapeutic
platforms into your clinical practice.
This Seminars and Tumor Board activity, based on a recent live symposium and
produced in collaboration with the Cholangiocarcinoma Foundation (CCF), pairs
real-world case scenarios with the practice-changing evidence that guides
treatment selection for the management of advanced BTCs. PeerView’s
collaboration with the CCF includes their educational resources and patient
stories to improve patient education, engagement in care, and shared
decision-making.
Target Audience
This activity has been designed to meet the educational needs of oncologists, gastroenterologists, advanced practice clinicians (NPs/PAs), and other relevant healthcare professionals involved in the management of biliary cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of modern and emerging therapeutic approaches, including immunotherapy and targeted platforms, for the management of BTC
- Utilize biomarker findings, current evidence, and guideline recommendations to build individualized treatment regimens for patients with advanced BTC
- Develop team-based strategies to address practical considerations of care, including patient education and AE management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Milind Javle, MD
Professor, Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Milind Javle, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.;
Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.;
GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen;
Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis
Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.;
Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co.
Ltd.
Faculty/Planner
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center (All
Regions)
Consortium Chair, Academic and Community Cancer Research United (ACCRU)
Phoenix, Arizona
Tanios Bekaii-Saab, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva
Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines;
Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity
Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact
Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.;
GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.;
Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.;
Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio
Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.;
Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation;
Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer;
Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios
Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer
Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene
Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte
Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati
Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle
Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute;
AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai
Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals,
Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents
WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to
Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CACHEXIA – Licensed to Recursion.
Faculty/Planner
Rachna Shroff, MD, MS, FASCO
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Associate Dean, Clinical and Translational Research, UA COM-T
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA COM-T)
Tucson, Arizona
Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim;
Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED
Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and
Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis,
Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.;
NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael
Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 18, 2025; credit is no longer available.
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
Groundbreaking science in personalized therapeutic approaches for advanced
biliary tract cancers (BTCs) has resulted in the expansion of a diverse
management model, empowering oncologists to battle the disease, as emerging
evidence continues to reshape treatment planning based on patient-specific
findings. These developments have led to the approval of several immune-based
and molecularly targeted therapies for the clinical management of advanced
BTCs. Through a case-based discussion, experts will provide valuable insight
on the practical aspects of integrating these new and emerging therapeutic
platforms into your clinical practice.
This Seminars and Tumor Board activity, based on a recent live symposium and
produced in collaboration with the Cholangiocarcinoma Foundation (CCF), pairs
real-world case scenarios with the practice-changing evidence that guides
treatment selection for the management of advanced BTCs. PeerView’s
collaboration with the CCF includes their educational resources and patient
stories to improve patient education, engagement in care, and shared
decision-making.
Target Audience
This activity has been designed to meet the educational needs of oncologists, gastroenterologists, advanced practice clinicians (NPs/PAs), and other relevant healthcare professionals involved in the management of biliary cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of modern and emerging therapeutic approaches, including immunotherapy and targeted platforms, for the management of BTC
- Utilize biomarker findings, current evidence, and guideline recommendations to build individualized treatment regimens for patients with advanced BTC
- Develop team-based strategies to address practical considerations of care, including patient education and AE management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Milind Javle, MD
Professor, Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Milind Javle, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.;
Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.;
GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen;
Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis
Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.;
Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co.
Ltd.
Faculty/Planner
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center (All
Regions)
Consortium Chair, Academic and Community Cancer Research United (ACCRU)
Phoenix, Arizona
Tanios Bekaii-Saab, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva
Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines;
Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity
Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact
Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.;
GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.;
Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.;
Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio
Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.;
Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation;
Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer;
Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios
Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer
Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene
Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte
Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati
Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle
Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute;
AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai
Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals,
Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents
WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to
Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CACHEXIA – Licensed to Recursion.
Faculty/Planner
Rachna Shroff, MD, MS, FASCO
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Associate Dean, Clinical and Translational Research, UA COM-T
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA COM-T)
Tucson, Arizona
Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim;
Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED
Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and
Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis,
Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.;
NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael
Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
StartThis activity expired on February 17, 2025; credit is no longer available.
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes
Activity Description
Despite their established role in the treatment of HR+, HER2- metastatic
breast cancer (MBC) and accumulating evidence supporting their adjuvant use
in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6
inhibitors and their use. While these agents were historically thought to be
largely similar and interchangeable, evolving data from clinical and
translational studies have shown that CDK4/6 inhibitors are not the same.
They have key differences in their chemical, biologic, pharmacologic, and
clinical features and different toxicity profiles, despite all being orally
bioavailable. Therefore, we must re-evaluate how we approach CDK4/6
inhibitors and integrate them into individualized treatment plans for
patients throughout the disease continuum, as well as consider what that
looks like in the real-world setting and how to make the most of them and
their distinct properties in the frontline setting and beyond?
In this activity, based on a recent live virtual workshop, learners receive
an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and
MBC, which provides the foundation for case-based discussions and tool-based
demonstrations of algorithmic decision aids designed to guide risk
assessment, candidate selection for therapy, and the optimal delivery of
treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC
before transitioning to HR+, HER2- MBC to demonstrate patient evaluation,
identify factors for prognostication, and model treatment planning,
selection, and sequencing throughout the advance disease continuum.
Additionally, the panel shares strategies to mitigate and manage common
adverse reactions associated with CDK4/6 inhibitors to improve treatment
adherence and persistence.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
- Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
- Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas,
Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.;
Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich
LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly;
Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation;
Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity
Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc;
Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene,
Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou)
Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian
Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis,
Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer
Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics;
eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD
Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM
Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.;
Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.;
Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio;
Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm;
Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics,
Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium
Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals
Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova
Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer;
PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics;
Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay
Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix
Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.;
Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc;
TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.;
Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics;
and Zymeworks Inc. (all paid to institution).
Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging
Center
New York, New York
Komal Jhaveri, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint
Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo
Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals
Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen
Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.;
Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita
Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion
Therapeutics; and Zymeworks Inc.
Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer
Research
Chelsea, London, United Kingdom
Professor Stephen Johnston, MA, PhD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and
Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and
Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 17, 2025; credit is no longer available.
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes
Activity Description
Despite their established role in the treatment of HR+, HER2- metastatic
breast cancer (MBC) and accumulating evidence supporting their adjuvant use
in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6
inhibitors and their use. While these agents were historically thought to be
largely similar and interchangeable, evolving data from clinical and
translational studies have shown that CDK4/6 inhibitors are not the same.
They have key differences in their chemical, biologic, pharmacologic, and
clinical features and different toxicity profiles, despite all being orally
bioavailable. Therefore, we must re-evaluate how we approach CDK4/6
inhibitors and integrate them into individualized treatment plans for
patients throughout the disease continuum, as well as consider what that
looks like in the real-world setting and how to make the most of them and
their distinct properties in the frontline setting and beyond?
In this activity, based on a recent live virtual workshop, learners receive
an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and
MBC, which provides the foundation for case-based discussions and tool-based
demonstrations of algorithmic decision aids designed to guide risk
assessment, candidate selection for therapy, and the optimal delivery of
treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC
before transitioning to HR+, HER2- MBC to demonstrate patient evaluation,
identify factors for prognostication, and model treatment planning,
selection, and sequencing throughout the advance disease continuum.
Additionally, the panel shares strategies to mitigate and manage common
adverse reactions associated with CDK4/6 inhibitors to improve treatment
adherence and persistence.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
- Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
- Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas,
Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.;
Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich
LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly;
Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation;
Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity
Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc;
Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene,
Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou)
Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian
Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis,
Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer
Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics;
eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD
Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM
Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.;
Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.;
Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio;
Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm;
Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics,
Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium
Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals
Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova
Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer;
PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics;
Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay
Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix
Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.;
Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc;
TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.;
Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics;
and Zymeworks Inc. (all paid to institution).
Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging
Center
New York, New York
Komal Jhaveri, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint
Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo
Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals
Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen
Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.;
Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita
Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion
Therapeutics; and Zymeworks Inc.
Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer
Research
Chelsea, London, United Kingdom
Professor Stephen Johnston, MA, PhD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and
Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and
Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
StartThis activity expired on February 16, 2025; credit is no longer available.
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: February 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
- Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
- Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo
Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca;
BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics.
Research funding goes to Institution.
Co-Chair/Planner
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, California
Catherine C. Coombs, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene
Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals,
Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-011-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 16, 2025; credit is no longer available.
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: February 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
- Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
- Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo
Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca;
BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics.
Research funding goes to Institution.
Co-Chair/Planner
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, California
Catherine C. Coombs, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene
Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals,
Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-011-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
StartThis activity expired on January 11, 2025; credit is no longer available.
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
Media: Enduring Material
Activity Release Date: January 12, 2024
Activity Expiration Date: January 11, 2025
Time to Complete Activity: 45 minutes
Activity Description
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
- Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
John L. Marshall, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca;
Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer
Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Other Financial or Material Support Executive role
for Indivumed GmbH.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-066-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of
75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 11, 2025; credit is no longer available.
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
Media: Enduring Material
Activity Release Date: January 12, 2024
Activity Expiration Date: January 11, 2025
Time to Complete Activity: 45 minutes
Activity Description
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
- Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
John L. Marshall, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca;
Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer
Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Other Financial or Material Support Executive role
for Indivumed GmbH.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-066-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of
75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView